Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study designed
to evaluate the safety, tolerability and efficacy of varespladib-methyl, concurrently with
standard of care (SOC), in subjects bitten by venomous snakes.